Axogen, Inc.

As of June 30, 2026, Axogen, Inc. has 53.18M shares outstanding.

As of June 30, 2026, Axogen, Inc. maintains a current ratio of 6.60, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.83, indicating elevated leverage, while an interest coverage ratio of -0.90 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Axogen, Inc. posted a negative return on equity (ROE) of -18.21, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -13.15, reflecting losses generated across the asset base. Inventory turnover of 1.52 indicates how many times Axogen, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Axogen, Inc. generated 4.39B in revenue and converted that into -586.14M in net income, yielding earnings per share of -11.67. EBITDA reached -65.78M, while operating income came in at -224.48M.

As of June 30, 2026, Axogen, Inc. holds 1.95B in cash and equivalents against 350.59M in total debt, resulting in a net debt position of -1.65B. Total book value stands at 4.48B, with working capital of 2.97B providing operational flexibility.

Axogen, Inc. produced 262.90M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -149.16M in capital expenditures, free cash flow totaled 113.74M - equivalent to 2.29 per share.

Over the twelve months ended June 30, 2026, Axogen, Inc. posted a gross margin of 74.56, reflecting its pricing power and cost economics. The operating margin of -5.12 and net profit margin of -13.36 provide insight into operational efficiency.